SAFETY DATA SHEET

XOLAIR(R) Vials (150 mg)

SECTION 1. IDENTIFICATION

Product name : XOLAIR(R) Vials (150 mg)
Product code : 00010183117
Common name(s), synonym(s) of the substance : XOLAIR Vials 150 mg, XOLAIR lyophilisat Vials 150 mg
Manufacturer or supplier's details
Company name of supplier : Genentech, Inc.
Address : DNA Way 1
          94080 South San Francisco
          CA
          USA
Telephone : 001-(650) 225-1000
E-mail address : info.sds@roche.com
Emergency telephone number : US Chemtrec phone (800)-424-9300

Recommended use of the chemical and restrictions on use
Recommended use : Formulated pharmaceutical active substance
Restrictions on use : For professional users only.

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with 29 CFR 1910.1200
Not a hazardous substance or mixture.

GHS label elements
Not a hazardous substance or mixture.

Other hazards
None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Omalizumab</td>
<td>242138-07-4</td>
<td>57.3</td>
</tr>
<tr>
<td>.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl</td>
<td>57-50-1</td>
<td>41.25</td>
</tr>
<tr>
<td>L-Histidine monohydrochloride monohydrate</td>
<td>5934-29-2</td>
<td>0.8</td>
</tr>
<tr>
<td>L-Histidine</td>
<td>71-00-1</td>
<td>0.5</td>
</tr>
<tr>
<td>Sorbitan, monododecanoate</td>
<td>9005-64-5</td>
<td>0.15</td>
</tr>
</tbody>
</table>
SECTION 4. FIRST AID MEASURES

General advice : Do not leave the victim unattended.

If inhaled : Move to fresh air.
If unconscious, place in recovery position and seek medical advice.
If symptoms persist, call a physician.

In case of skin contact : If on skin, rinse well with water.

In case of eye contact : Immediately flush eye(s) with plenty of water.
Remove contact lenses.
Protect unharmed eye.
If eye irritation persists, consult a specialist.

If swallowed : Keep respiratory tract clear.
Do not give milk or alcoholic beverages.
Never give anything by mouth to an unconscious person.
If symptoms persist, call a physician.
Rinse mouth with water.

Most important symptoms and effects, both acute and delayed : None known.

Notes to physician : The first aid procedure should be established in consultation with the doctor responsible for industrial medicine.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

Specific hazards during fire fighting : No information available.

Hazardous combustion products : In case of fire hazardous decomposition products may be produced such as:
Carbon monoxide
Nitrogen oxides (NOx)
Sulfur oxides

Further information : Standard procedure for chemical fires.
Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

Special protective equipment for fire-fighters : Wear self-contained breathing apparatus for firefighting if necessary.

SECTION 6. ACCIDENTAL RELEASE MEASURES
SAFETY DATA SHEET

XOLAIR(R) Vials (150 mg)

Version 1.0
Revision Date: 02-07-2020
Date of last issue: -
Date of first issue: 02-07-2020

Personal precautions, protective equipment and emergency procedures:
Avoid dust formation.

Environmental precautions:
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up:
Pick up and arrange disposal without creating dust.
Sweep up and shovel.
Keep in suitable, closed containers for disposal.

SECTION 7. HANDLING AND STORAGE

Advice on protection against fire and explosion:
Provide appropriate exhaust ventilation at places where dust is formed.

Advice on safe handling:
For personal protection see section 8. Smoking, eating and drinking should be prohibited in the application area.

Conditions for safe storage:
Electrical installations / working materials must comply with the technological safety standards.

Further information on storage conditions:
See label, package insert or internal guidelines

Materials to avoid:
No materials to be especially mentioned.

Storage temperature:
2 °C to 8 °C
Protected from heat and light

Further information on storage stability:
No decomposition if stored and applied as directed.

Packaging material:
Suitable material: glass, glass bottles

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Omalizumab</td>
<td>242138-07-4</td>
<td>IOEL</td>
<td>0.02 mg/m³</td>
<td>Roche Industrial Hygiene Committee (RIHC)</td>
</tr>
<tr>
<td>.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl</td>
<td>57-50-1</td>
<td>TWA</td>
<td>10 mg/m³</td>
<td>NIOSH REL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (Respirable)</td>
<td>5 mg/m³</td>
<td></td>
</tr>
</tbody>
</table>
**SAFETY DATA SHEET**

**XOLAIR(R) Vials (150 mg)**

<table>
<thead>
<tr>
<th>Engineering measures</th>
<th>:</th>
<th>No data available</th>
</tr>
</thead>
<tbody>
<tr>
<td>Personal protective equipment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Respiratory protection</td>
<td>:</td>
<td>No personal respiratory protective equipment normally required.</td>
</tr>
<tr>
<td>Hand protection</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Material</td>
<td>:</td>
<td>Protective gloves</td>
</tr>
<tr>
<td>Remarks</td>
<td>:</td>
<td>Wear appropriate protective gloves to prevent skin contact. Replace torn or punctured gloves promptly.</td>
</tr>
<tr>
<td>Eye protection</td>
<td>:</td>
<td>Safety glasses</td>
</tr>
<tr>
<td>Skin and body protection</td>
<td>:</td>
<td>Protective suit</td>
</tr>
<tr>
<td>Hygiene measures</td>
<td>:</td>
<td>Handle in accordance with good industrial hygiene and safety practice.</td>
</tr>
</tbody>
</table>

**SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

<table>
<thead>
<tr>
<th>Property</th>
<th>:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Appearance</td>
<td>: solid, (lyophilized)</td>
</tr>
<tr>
<td>Color</td>
<td>: white</td>
</tr>
<tr>
<td>Odor</td>
<td>: Not applicable</td>
</tr>
<tr>
<td>Odor Threshold</td>
<td>: Not applicable</td>
</tr>
<tr>
<td>pH</td>
<td>: Not applicable</td>
</tr>
<tr>
<td>Melting point/range</td>
<td>: No data available</td>
</tr>
<tr>
<td>Boiling point/boiling range</td>
<td>: No data available</td>
</tr>
<tr>
<td>Flash point</td>
<td>: does not flash</td>
</tr>
<tr>
<td>Evaporation rate</td>
<td>: No data available</td>
</tr>
<tr>
<td>Self-ignition</td>
<td>: No data available</td>
</tr>
</tbody>
</table>
Upper explosion limit / Upper flammability limit : No data available
Lower explosion limit / Lower flammability limit : No data available
Vapor pressure : No data available
Relative vapor density : Not applicable
Relative density : No data available
Solubility(ies)
  Water solubility : completely miscible
  Solubility in other solvents : No data available
Partition coefficient: n-octanol/water : No data available
Autoignition temperature : No data available
Decomposition temperature : No data available
Viscosity
  Viscosity, dynamic : Not applicable
  Viscosity, kinematic : Not applicable
Explosive properties : No data available
Oxidizing properties : No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity : No dangerous reaction known under conditions of normal use.
Chemical stability : Stable under normal conditions. Proteins are temperature-sensitive; the thermal denaturation has an impact on quality but does not affect Plant and Process Safety; during decomposition no flammable gas, no organic peroxide and no oxidising substances are created
Possibility of hazardous reactions : Stable under recommended storage conditions. No hazards to be specially mentioned.
Conditions to avoid : No data available
Incompatible materials : No data available
Hazardous decomposition products : No data available
SECTION 11. TOXICOLOGICAL INFORMATION

**Acute toxicity**
Not classified based on available information.

**Components:**

**Omalizumab:**
Acute oral toxicity: Remarks: Not bioavailable by oral administration
Acute toxicity (other routes of administration): LD0 (Monkey): 200 mg/kg Application Route: i.v.

**.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:**
Acute oral toxicity: LD50 Oral (Rat): 29,700 mg/kg LD50 Oral (Mouse): 14,000 mg/kg
Acute inhalation toxicity: Acute toxicity estimate: > 30 mg/l Test atmosphere: dust/mist Method: Expert judgment
Acute dermal toxicity: Acute toxicity estimate: > 5,001 mg/kg Method: Expert judgment

**Skin corrosion/irritation**
Not classified based on available information.

**Serious eye damage/eye irritation**
Not classified based on available information.

**Respiratory or skin sensitization**

**Skin sensitization**
Not classified based on available information.

**Respiratory sensitization**
Not classified based on available information.

**Germ cell mutagenicity**
Not classified based on available information.

**Components:**

**Omalizumab:**
Genotoxicity in vitro: Test Type: Ames test Test system: Salmonella typhimurium Metabolic activation: with and without metabolic activation Result: negative

**Carcinogenicity**
Not classified based on available information.
Components:

**.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:**

**Remarks:** No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

**IARC**

No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

**OSHA**

No component of this product present at levels greater than or equal to 0.1% is on OSHA’s list of regulated carcinogens.

**NTP**

No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

**Reproductive toxicity**

Not classified based on available information.

Components:

**Omalizumab:**

**Effects on fetal development**

Species: cynomolgus monkey, female
Application Route: s.c.
General Toxicity Maternal: NOAEL: 75 mg/kg bw/day
Embryo-fetal toxicity: NOAEL: 75 mg/kg bw/day
Result: No adverse effects.

**STOT-single exposure**

Not classified based on available information.

Components:

**.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:**

**Assessment**

The substance or mixture is not classified as specific target organ toxicant, single exposure.

**STOT-repeated exposure**

Not classified based on available information.

Components:

**.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:**

**Assessment**

The substance or mixture is not classified as specific target organ toxicant, repeated exposure.

**Repeated dose toxicity**

Components:

**Omalizumab:**

Species: cynomolgus monkey
LOEL: 30 mg/kg/w
Application Route: s.c.
Exposure time: 26 Weeks
Aspiration toxicity
Not classified based on available information.

Components:
.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:
No data available

Further information

Components:
Omalizumab:
Remarks: anaphylactic reactions may occur following the intravenous application of proteins; rare cases of hypersensitivity have been described with other monoclonal antibodies

Components:
.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:
Remarks: Health injuries are not known or expected under normal use.

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:
.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:
Toxicity to fish: LC50: > 100 mg/l
Exposure time: 96 h

Ecotoxicology Assessment
Acute aquatic toxicity: This product has no known ecotoxicological effects.
Chronic aquatic toxicity: This product has no known ecotoxicological effects.
Toxicity Data on Soil: Not expected to adsorb on soil.
Other organisms relevant to the environment: No data available

Persistence and degradability

Components:
Omalizumab:
Biodegradability: Result: Globular proteins are generally well biodegradable
Bioaccumulative potential

**Components:**

**Omalizumab:**
Partition coefficient: n-octanol/water
Remarks: No data available

**.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:**
Partition coefficient: n-octanol/water
log Pow: -3.67

Mobility in soil
No data available

Other adverse effects

**Product:**
Ozone-Depletion Potential
Regulation: 40 CFR Protection of Environment; Part 82
Protection of Stratospheric Ozone - CAA Section 602 Class I Substances
Remarks: This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).

**Components:**

**Omalizumab:**
Additional ecological information
Monoclonal antibodies are proteins with highly specific affinity to a certain antigen; therefore, no appreciable ecotoxic potential is to be expected

---

**SECTION 13. DISPOSAL CONSIDERATIONS**

**Disposal methods**
Waste from residues
Can be disposed as waste water, when in compliance with local regulations.

Contaminated packaging
Empty containers should be taken to an approved waste handling site for recycling or disposal. Do not re-use empty containers.

---

**SECTION 14. TRANSPORT INFORMATION**

**International Regulations**

**UNRTDG**
Not regulated as a dangerous good

**IATA-DGR**
SAFETY DATA SHEET

XOLAIR(R) Vials (150 mg)

Version: 1.0
Revision Date: 02-07-2020
Date of last issue: -
Date of first issue: 02-07-2020

Not regulated as a dangerous good

IMDG-Code
Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable

Domestic regulation

49 CFR
Not regulated as a dangerous good

SECTION 15. REGULATORY INFORMATION

EPCRA - Emergency Planning and Community Right-to-Know

CERCLA Reportable Quantity
This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity
This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Component TPQ (lbs)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARA 311/312 Hazards</td>
<td>No SARA Hazards</td>
<td></td>
</tr>
</tbody>
</table>

Clean Air Act
This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B). This product does not contain any hazardous air pollutants (HAP), as defined by the U.S. Clean Air Act Section 112 (40 CFR 61). This product does not contain any chemicals listed under the U.S. Clean Air Act Section 112(r) for Accidental Release Prevention (40 CFR 68.130, Subpart F). This product does not contain any chemicals listed under the U.S. Clean Air Act Section 111 SOCMIs Intermediate or Final VOC's (40 CFR 60.489).

Clean Water Act
This product does not contain any Hazardous Substances listed under the U.S. Clean Water Act, Section 311, Table 116.4A. This product does not contain any Hazardous Chemicals listed under the U.S. Clean Water Act, Section 311, Table 117.3. This product does not contain any toxic pollutants listed under the U.S. Clean Water Act Section 307.

US State Regulations

Massachusetts Right To Know
.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl 57-50-1

Pennsylvania Right To Know
Omalizumab 242138-07-4
.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl 57-50-1
Maine Chemicals of High Concern

Vermont Chemicals of High Concern

Washington Chemicals of High Concern

California Permissible Exposure Limits for Chemical Contaminants

\[ \text{.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl} \ 57-50-1 \]

The ingredients of this product are reported in the following inventories:

- **DSL**: This product contains the following components that are not on the Canadian DSL nor NDSL.
  - Omalizumab
  - L-Histidine monohydrochloride monohydrate

- **AICS**: Not in compliance with the inventory

- **NZIoC**: On the inventory, or in compliance with the inventory

- **ENCS**: Not in compliance with the inventory

- **ISHL**: Not in compliance with the inventory

- **KECI**: Not in compliance with the inventory

- **PICCS**: Not in compliance with the inventory

- **IECSC**: Not in compliance with the inventory

- **TCSI**: Not in compliance with the inventory

- **TSCA**: Substance(s) not listed on TSCA inventory

**TSCA list**

No substances are subject to a Significant New Use Rule.

No substances are subject to TSCA 12(b) export notification requirements.

---

**SECTION 16. OTHER INFORMATION**
SAFETY DATA SHEET

XOLAIR(R) Vials (150 mg)

Version 1.0
Revision Date: 02-07-2020
Date of last issue: -
Date of first issue: 02-07-2020

NFPA:

HMIS® IV:

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)
NIOSH REL : USA. NIOSH Recommended Exposure Limits
OSHA P0 : USA. OSHA - TABLE Z-1 Limits for Air Contaminants - 1910.1000
OSHA Z-1 : USA. Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants
ACGIH / TWA : 8-hour, time-weighted average
NIOSH REL / TWA : Time-weighted average concentration for up to a 10-hour workday during a 40-hour workweek
OSHA P0 / TWA : 8-hour time weighted average
OSHA Z-1 / TWA : 8-hour time weighted average

AICS - Australian Inventory of Chemical Substances; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals

12 / 13
SAFETY DATA SHEET

XOLAIR(R) Vials (150 mg)

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date</th>
<th>Date of last issue</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.0</td>
<td>02-07-2020</td>
<td>-</td>
</tr>
</tbody>
</table>

The information provided in this Material Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text.

Revision Date : 02-07-2020

US / Z8 / 1810